kb-1389

Ixekizumab

Home » Antibody » Ixekizumab

Background

Ixekizumab, a humanized monoclonal antibody belonging to the immunoglobulin G subclass 4 (IgG4), targets interleukin-17A (IL-17A) by hindering its interaction with the IL-17A receptor. Given IL-17A's crucial involvement as a pro-inflammatory cytokine in inciting inflammation and orchestrating immune responses, the blockade of its effects proves advantageous in managing inflammatory conditions. Notably, IL-17A's association with various autoimmune diseases, such as Rheumatoid Arthritis and plaque psoriasis, underscores its significance in disease pathogenesis. By neutralizing IL-17A, ixekizumab manifests as a promising therapeutic agent in ameliorating the symptoms and addressing the underlying mechanisms implicated in these autoimmune disorders.

Specifications

Catalog Number:
kb-1389
Cell Line Name:
Ixekizumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
IL17A
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J: LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010 Apr;62(4):929-39. 2. Bush KA, Farmer KM, Walker JS, Kirkham BW: Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002 Mar;46(3):802-5.
Please enable JavaScript in your browser to complete this form.